Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.

Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF, Gores GJ.

J Hepatol. 2018 May 24. pii: S0168-8278(18)32064-6. doi: 10.1016/j.jhep.2018.05.018. [Epub ahead of print]

PMID:
29802947
2.

Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging.

Robinson AR, Yousefzadeh MJ, Rozgaja TA, Wang J, Li X, Tilstra JS, Feldman CH, Gregg SQ, Johnson CH, Skoda EM, Frantz MC, Bell-Temin H, Pope-Varsalona H, Gurkar AU, Nasto LA, Robinson RAS, Fuhrmann-Stroissnigg H, Czerwinska J, McGowan SJ, Cantu-Medellin N, Harris JB, Maniar S, Ross MA, Trussoni CE, LaRusso NF, Cifuentes-Pagano E, Pagano PJ, Tudek B, Vo NV, Rigatti LH, Opresko PL, Stolz DB, Watkins SC, Burd CE, Croix CMS, Siuzdak G, Yates NA, Robbins PD, Wang Y, Wipf P, Kelley EE, Niedernhofer LJ.

Redox Biol. 2018 Jul;17:259-273. doi: 10.1016/j.redox.2018.04.007. Epub 2018 Apr 13.

3.

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes in PSC: A Derivation & Validation Study Using Machine Learning.

Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.

Hepatology. 2018 May 9. doi: 10.1002/hep.30085. [Epub ahead of print]

PMID:
29742811
4.

MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma.

Mansini AP, Lorenzo Pisarello MJ, Thelen KM, Cruz-Reyes M, Peixoto E, Jin S, Howard BN, Trussoni CE, Gajdos GB, LaRusso NF, Perugorria MJ, Banales JM, Gradilone SA.

Hepatology. 2018 Feb 6. doi: 10.1002/hep.29832. [Epub ahead of print]

PMID:
29406621
5.

Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.

Lorenzo Pisarello M, Masyuk TV, Gradilone SA, Masyuk AI, Ding JF, Lee PY, LaRusso NF.

Am J Pathol. 2018 Apr;188(4):981-994. doi: 10.1016/j.ajpath.2017.12.016. Epub 2018 Jan 31.

PMID:
29366679
6.

Cholangiocytes in health and disease: From basic science to novel treatments.

Banales JM, Marzioni M, LaRusso NF, Jansen P.

Biochim Biophys Acta. 2018 Apr;1864(4 Pt B):1217-1219. doi: 10.1016/j.bbadis.2018.01.014. Epub 2018 Jan 31. No abstract available.

7.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

PMID:
29220537
8.

Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis.

Masyuk TV, Masyuk AI, LaRusso NF.

Hepatology. 2018 Jun;67(6):2462-2464. doi: 10.1002/hep.29708. Epub 2018 Apr 19. No abstract available.

PMID:
29211938
9.

Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.

Masyuk AI, Masyuk TV, Lorenzo Pisarello MJ, Ding JF, Loarca L, Huang BQ, LaRusso NF.

Hepatology. 2018 Mar;67(3):1088-1108. doi: 10.1002/hep.29577. Epub 2018 Feb 1.

PMID:
29023824
10.

MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.

Erice O, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, Santos-Laso A, Arbelaiz A, Jimenez-Agüero R, Fernandez-Irigoyen J, Santamaria E, Torrano V, Carracedo A, Ananthanarayanan M, Marzioni M, Prieto J, Beuers U, Oude Elferink RP, LaRusso NF, Bujanda L, Marin JJG, Banales JM.

Hepatology. 2018 Apr;67(4):1420-1440. doi: 10.1002/hep.29533. Epub 2018 Feb 21.

PMID:
28922472
11.

A 59-Year-Old Man With New Jaundice.

Mouchli MA, Kurtin PJ, LaRusso NF.

Gastroenterology. 2018 Jun;154(8):2035-2036. doi: 10.1053/j.gastro.2017.09.003. Epub 2017 Sep 9. No abstract available.

PMID:
28899720
12.

Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis.

Loarca L, De Assuncao TM, Jalan-Sakrikar N, Bronk S, Krishnan A, Huang B, Morton L, Trussoni C, Bonilla LM, Krueger E, O'Hara S, Splinter P, Shi G, Pisarello MJL, Gores GJ, Huebert RC, LaRusso NF.

Lab Invest. 2017 Nov;97(11):1385-1396. doi: 10.1038/labinvest.2017.63. Epub 2017 Sep 11.

13.

Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.

Moncsek A, Al-Suraih MS, Trussoni CE, O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, Zhu Y, Tchkonia T, Kirkland JL, Gores GJ, Müllhaupt B, LaRusso NF, Mertens JC.

Hepatology. 2018 Jan;67(1):247-259. doi: 10.1002/hep.29464. Epub 2017 Nov 29.

PMID:
28802066
14.

Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?

O'Hara SP, Karlsen TH, LaRusso NF.

Gut. 2017 Nov;66(11):1873-1877. doi: 10.1136/gutjnl-2017-314249. Epub 2017 Jul 21. No abstract available.

15.

Pathobiology of biliary epithelia.

Cheung AC, Lorenzo Pisarello MJ, LaRusso NF.

Biochim Biophys Acta. 2018 Apr;1864(4 Pt B):1220-1231. doi: 10.1016/j.bbadis.2017.06.024. Epub 2017 Jul 15. Review.

16.

Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Cheung AC, LaRusso NF, Gores GJ, Lazaridis KN.

Semin Liver Dis. 2017 May;37(2):159-174. doi: 10.1055/s-0037-1603324. Epub 2017 May 31. No abstract available.

17.

TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.

Masyuk TV, Masyuk AI, Lorenzo Pisarello M, Howard BN, Huang BQ, Lee PY, Fung X, Sergienko E, Ardecky RJ, Chung TDY, Pinkerton AB, LaRusso NF.

Hepatology. 2017 Oct;66(4):1197-1218. doi: 10.1002/hep.29284. Epub 2017 Aug 26.

PMID:
28543567
18.

Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.

Cheung AC, Juran BD, Moore RM, LaRusso NF, Lazaridis KN.

J Hepatol. 2017 Sep;67(3):651-652. doi: 10.1016/j.jhep.2017.02.036. Epub 2017 Apr 29. No abstract available.

19.

B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y.

Kidney Int. 2017 Sep;92(3):657-668. doi: 10.1016/j.kint.2017.02.017. Epub 2017 Apr 14.

PMID:
28416225
20.

Emerging pharmacologic therapies for primary sclerosing cholangitis.

Cheung AC, Lazaridis KN, LaRusso NF, Gores GJ.

Curr Opin Gastroenterol. 2017 May;33(3):149-157. doi: 10.1097/MOG.0000000000000352. Review.

21.

Role of the Intestinal Microbiome in Cholestatic Liver Disease.

LaRusso NF, Tabibian JH, O'Hara SP.

Dig Dis. 2017;35(3):166-168. doi: 10.1159/000450906. Epub 2017 Mar 1. Review.

22.

ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A.

O'Hara SP, Splinter PL, Trussoni CE, Pisarello MJ, Loarca L, Splinter NS, Schutte BF, LaRusso NF.

J Biol Chem. 2017 Mar 24;292(12):4833-4846. doi: 10.1074/jbc.M117.777409. Epub 2017 Feb 8.

23.

Primary Sclerosing Cholangitis.

Lazaridis KN, LaRusso NF.

N Engl J Med. 2016 Dec 22;375(25):2501-2502. doi: 10.1056/NEJMc1613273. No abstract available.

24.

Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease.

Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, LaRusso NF, Watt KD, Cramer CH, Leung N.

Hepatol Int. 2017 Jul;11(4):384-389. doi: 10.1007/s12072-016-9775-9. Epub 2016 Dec 8.

PMID:
27933591
25.

Extracellular vesicles in liver pathobiology: Small particles with big impact.

Hirsova P, Ibrahim SH, Verma VK, Morton LA, Shah VH, LaRusso NF, Gores GJ, Malhi H.

Hepatology. 2016 Dec;64(6):2219-2233. doi: 10.1002/hep.28814. Epub 2016 Oct 20. Review.

26.

Primary Sclerosing Cholangitis.

Lazaridis KN, LaRusso NF.

N Engl J Med. 2016 Sep 22;375(12):1161-70. doi: 10.1056/NEJMra1506330. Review. No abstract available.

27.

Polycystic Liver Disease: The Benefits of Targeting cAMP.

Larusso NF, Masyuk TV, Hogan MC.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1031-4. doi: 10.1016/j.cgh.2016.03.008. Epub 2016 Mar 10. No abstract available.

28.

An Octogenarian With Acute Epigastric Pain: More Than Meets the Eye.

Lynn A, Tabibian JH, LaRusso NF.

Gastroenterology. 2016 Feb;150(2):e5-6. doi: 10.1053/j.gastro.2015.06.052. Epub 2015 Dec 23. No abstract available.

PMID:
26724265
29.

Performance of magnetic resonance elastography in primary sclerosing cholangitis.

Eaton JE, Dzyubak B, Venkatesh SK, Smyrk TC, Gores GJ, Ehman RL, LaRusso NF, Gossard AA, Lazaridis KN.

J Gastroenterol Hepatol. 2016 Jun;31(6):1184-90. doi: 10.1111/jgh.13263.

30.

Hail to the chief-Keith Lindor, our new AASLD president.

Shah VH, Gores GJ, LaRusso NF.

Hepatology. 2016 Feb;63(2):357-9. doi: 10.1002/hep.28342. Epub 2015 Dec 18. No abstract available.

PMID:
26566704
31.

The enteric microbiome in hepatobiliary health and disease.

Tabibian JH, Varghese C, LaRusso NF, O'Hara SP.

Liver Int. 2016 Apr;36(4):480-7. doi: 10.1111/liv.13009. Epub 2015 Dec 12. Review.

32.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.

Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.

33.

TGR5 in the Cholangiociliopathies.

Masyuk TV, Masyuk AI, LaRusso NF.

Dig Dis. 2015;33(3):420-5. doi: 10.1159/000371696. Epub 2015 May 27.

34.

Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Tabibian JH, O'Hara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajjed T, Hagey LR, LaRusso NF.

Hepatology. 2016 Jan;63(1):185-96. doi: 10.1002/hep.27927. Epub 2015 Aug 10.

35.

Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM.

J Hepatol. 2015 Oct;63(4):952-61. doi: 10.1016/j.jhep.2015.05.023. Epub 2015 Jun 1.

36.

The Cholangiopathies.

Lazaridis KN, LaRusso NF.

Mayo Clin Proc. 2015 Jun;90(6):791-800. doi: 10.1016/j.mayocp.2015.03.017. Epub 2015 May 6. Review.

37.

Therapeutic Targets in Polycystic Liver Disease.

Masyuk TV, Masyuk AI, LaRusso NF.

Curr Drug Targets. 2017;18(8):950-957. doi: 10.2174/1389450116666150427161743. Review.

38.

Microbiome-Immune Interactions and Liver Disease.

Tabibian JH, Varghese C, O'Hara SP, LaRusso NF.

Clin Liver Dis (Hoboken). 2015 Apr;5(4):83-85. doi: 10.1002/cld.453. Epub 2015 May 7. No abstract available.

39.

The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.

Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, Palmer AK, Ikeno Y, Hubbard GB, Lenburg M, O'Hara SP, LaRusso NF, Miller JD, Roos CM, Verzosa GC, LeBrasseur NK, Wren JD, Farr JN, Khosla S, Stout MB, McGowan SJ, Fuhrmann-Stroissnigg H, Gurkar AU, Zhao J, Colangelo D, Dorronsoro A, Ling YY, Barghouthy AS, Navarro DC, Sano T, Robbins PD, Niedernhofer LJ, Kirkland JL.

Aging Cell. 2015 Aug;14(4):644-58. doi: 10.1111/acel.12344. Epub 2015 Apr 22.

40.

Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.

Gradilone SA, Pisarello MJL, LaRusso NF.

Curr Drug Targets. 2017;18(8):958-963. doi: 10.2174/1389450116666150223162737. Review.

41.

MicroRNAs and benign biliary tract diseases.

Gradilone SA, O'Hara SP, Masyuk TV, Pisarello MJ, LaRusso NF.

Semin Liver Dis. 2015 Feb;35(1):26-35. doi: 10.1055/s-0034-1397346. Epub 2015 Jan 29. Review.

42.

Polycystic liver diseases: advanced insights into the molecular mechanisms.

Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, Banales JM.

Nat Rev Gastroenterol Hepatol. 2014 Dec;11(12):750-61. doi: 10.1038/nrgastro.2014.155. Epub 2014 Sep 30. Review.

43.

MicroRNAs in Cholangiopathies.

O'Hara SP, Gradilone SA, Masyuk TV, Tabibian JH, LaRusso NF.

Curr Pathobiol Rep. 2014 Sep 1;2(3):133-142.

44.

Calcium signaling in cilia and ciliary-mediated intracellular calcium signaling: are they independent or coordinated molecular events?

Masyuk AI, Gradilone SA, LaRusso NF.

Hepatology. 2014 Nov;60(5):1783-5. doi: 10.1002/hep.27331. Epub 2014 Oct 2. No abstract available.

45.

Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis.

Tabibian JH, Trussoni CE, O'Hara SP, Splinter PL, Heimbach JK, LaRusso NF.

Lab Invest. 2014 Oct;94(10):1126-33. doi: 10.1038/labinvest.2014.94. Epub 2014 Jul 21.

46.

Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Urribarri AD, Munoz-Garrido P, Perugorria MJ, Erice O, Merino-Azpitarte M, Arbelaiz A, Lozano E, Hijona E, Jiménez-Agüero R, Fernandez-Barrena MG, Jimeno JP, Marzioni M, Marin JJ, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Banales JM.

Gut. 2014 Oct;63(10):1658-67. doi: 10.1136/gutjnl-2013-305281. Epub 2014 Jan 16.

47.

HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, Larusso NF.

Am J Pathol. 2014 Mar;184(3):600-8. doi: 10.1016/j.ajpath.2013.11.027. Epub 2014 Jan 13.

48.

Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.

Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, LaRusso NF.

Hepatology. 2014 Jun;59(6):2263-75. doi: 10.1002/hep.26993. Epub 2014 Apr 25.

49.

Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.

Masyuk TV, Lee SO, Radtke BN, Stroope AJ, Huang B, Banales JM, Masyuk AI, Splinter PL, Gradilone SA, Gajdos GB, LaRusso NF.

Am J Pathol. 2014 Jan;184(1):110-21. doi: 10.1016/j.ajpath.2013.09.021. Epub 2013 Nov 7.

50.

Role for Krüppel-like transcription factor 11 in mesenchymal cell function and fibrosis.

Mathison A, Grzenda A, Lomberk G, Velez G, Buttar N, Tietz P, Hendrickson H, Liebl A, Xiong YY, Gores G, Fernandez-Zapico M, Larusso NF, Faubion W, Shah VH, Urrutia R.

PLoS One. 2013 Sep 17;8(9):e75311. doi: 10.1371/journal.pone.0075311. eCollection 2013.

Supplemental Content

Loading ...
Support Center